Among ASCO ’16’s outstanding clinical highlights were a Herceptin biosimilar that may be a game-changer, the MyPathway basket trial, and the promise of liquid biopsies. ...
At ASCO, tumor mutation burden and mismatch repair deficiency, in addition to PD-L1 expression, were reported as possible biomarkers for immunotherapy. An in-depth look at the new data from ASCO across multiple tumor types. ...
We explore what was hot in monoclonal antibodies for multiple myeloma at ASCO with a look at phase 3 trial results of daratumumab (CASTOR), elotuzumab (ELOQUENT-2) and more. We also examine the cost of new therapies. ...
Hem/oncs tell all about their ASCO Experience—survey results from ZS enlighten us as to what made an impression on physicians at the annual meeting....